Chimeric antigen receptor-modified (CAR) T cells targeting CD19 have revolutionized the
treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has …

Lymphomas are heterogeneous tumors with striking genetic diversity and variable outcomes
even within pathologic diagnoses. Treatment response assessment relies on radiologic and …

Chimeric antigen receptor (CAR) T-cell therapy provides long-term remissions in patients
with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Total metabolic tumor …

Chimeric antigen receptor-engineered T (CART) cells are a promising new treatment option
for patients with multiply relapsed and refractory (R/R) diffuse large B cell lymphoma …

Chimeric antigen receptor (CAR) T cells (CART) therapies have changed and continue to
change the treatment paradigms for B‐cell malignancies because they can achieve durable …

Patients with refractory or relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL) and
highly aggressive B cell non-Hodgkin lymphoma (B-NHL) have a very dismal prognosis and …

The aim of this study was to evaluate the prognostic impact of the F-fluorodeoxyglucose
positron emission tomography response at 1 month (M1) and 3 months (M3) after anti-CD19 …

Chimeric antigen receptor (CAR) T cell therapy holds enormous potential for the treatment of
hematologic malignancies. Despite its benefits, it is still used as a second line of therapy …

Diffuse large B-cell lymphoma (DLBCL) is a common, genomically heterogenous disease
that presents a clinical challenge despite the success of frontline regimens and second-line …

The aim of this study was to evaluate the prognostic impact of the FDG-PET response at one
month (M1) and three months (M3) after anti-CD19 CAR T-cells in a multicenter cohort of …